EUVIMEDEUVIMED entdecken
Open Access

B cell extracellular vesicles influence melanoma response to immune checkpoint therapy

Ala'a Al Hrout iD, Agshin Balayev, Karla Cervantes-Gracia, Konstantinos Gkelis, Stephan Benke iD, Julia M Matínez Gómez iD, Karina Silina iD, Mitchell P Levesque iD, Richard Chahwan iD

Science Advances · 2025

DOI: 10.1126/sciadv.adt4551 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Ala'a Al Hrout und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. Hauptthemen laut MEDLINE: Extracellular Vesicles, Melanoma, B-Lymphocytes, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The immune tumor microenvironment is a dynamic ecosystem where B cells play critical roles in modulating immune checkpoint blockade (ICB) therapy responses. While traditionally seen as passive players in tumor immunity, recent evidence suggests that B cells actively influence antitumor responses. This study examines the role of B cells and their extracellular vesicles (EVs) in melanoma responses to ICB. Retrospective meta-analyses reveal increased B cell enrichment in ICB responders’ pretreatment. Functional assays show that B cell depletion impairs T cell–mediated tumor cytotoxicity. EVs from melanoma tumors were analyzed, identifying miR-99a-5p in CD19 + EVs as up-regulated in responders. Silencing miR-99a-5p in B cells reduces T cell antitumor activity, suggesting its role in immune modulation. Mechanistically, miR-99a-5p promotes B cell maturation via class-switch recombination. These findings underscore B cells’ impact on melanoma immunotherapy, offering insights into novel therapeutic strategies targeting B cell–related pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesMelanomaB-LymphocytesImmune Checkpoint InhibitorsHumansTumor MicroenvironmentMicroRNAsCell Line, TumorAnimalsT-LymphocytesImmunotherapyMice

Substanzen

Immune Checkpoint InhibitorsMicroRNAs

Autor:innen und Institutionen

  • Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
  • Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zurich), 8093 Zurich, Switzerland.
  • Flow Cytometry Facility, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
  • Department of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
  • EVIIVE AG, 8057 Zurich, Switzerland.

ORCID-Profile: Ala'a Al Hrout, Stephan Benke, Julia M Matínez Gómez, Karina Silina, Mitchell P Levesque, Richard Chahwan

Zitieren

APA

Al Hrout, A., Balayev, A., Cervantes-Gracia, K., Gkelis, K., Benke, S., Matínez Gómez, J. M., Silina, K., Levesque, M. P., & Chahwan, R. (2025). B cell extracellular vesicles influence melanoma response to immune checkpoint therapy. Science Advances. https://doi.org/10.1126/sciadv.adt4551

Vancouver

Al Hrout A, Balayev A, Cervantes-Gracia K, Gkelis K, Benke S, Matínez Gómez JM, et al. B cell extracellular vesicles influence melanoma response to immune checkpoint therapy. Science Advances. 2025. doi:10.1126/sciadv.adt4551

BibTeX
@article{AlHrout2025,
  author = {Al Hrout, Ala'a and Balayev, Agshin and Cervantes-Gracia, Karla and Gkelis, Konstantinos and Benke, Stephan and Matínez Gómez, Julia M and Silina, Karina and Levesque, Mitchell P and Chahwan, Richard},
  title = {B cell extracellular vesicles influence melanoma response to immune checkpoint therapy},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adt4551}
}
Kostenlos starten →